Listed

Sanofi: Form 20-F for the period ended Dec 31, 2025

Filed with the SEC on Feb 17, 2026 and accepted by EDGAR at Feb 17, 2026, 12:34 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2025-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Cost of revenue12 months2025-01-01 to 2025-12-31EUR 13.05bnifrs-full:CostOfSales
Gross profit12 months2025-01-01 to 2025-12-31EUR 33.67bnifrs-full:GrossProfit
Operating income12 months2025-01-01 to 2025-12-31EUR 6.34bnifrs-full:ProfitLossFromOperatingActivities
Income tax12 months2025-01-01 to 2025-12-31EUR 1.04bnifrs-full:IncomeTaxExpenseContinuingOperations
Net income12 months2025-01-01 to 2025-12-31EUR 7.81bnifrs-full:ProfitLossAttributableToOwnersOfParent
Diluted EPS12 months2025-01-01 to 2025-12-31EUR 6.37ifrs-full:DilutedEarningsLossPerShare
Basic EPS12 months2025-01-01 to 2025-12-31EUR 6.40ifrs-full:BasicEarningsLossPerShare
Operating cash flow12 months2025-01-01 to 2025-12-31EUR 10.75bnifrs-full:CashFlowsFromUsedInOperatingActivities
Cash and equivalentsAt period end2025-12-31EUR 7.66bnifrs-full:CashAndCashEquivalents
Current assetsAt period end2025-12-31EUR 30.95bnifrs-full:CurrentAssets
Total assetsAt period end2025-12-31EUR 126.81bnifrs-full:Assets
Current liabilitiesAt period end2025-12-31EUR 28.34bnifrs-full:CurrentLiabilities
Shareholders' equityAt period end2025-12-31EUR 71.38bnifrs-full:EquityAttributableToOwnersOfParent
Shares outstandingAt period end2025-12-311,219,427,096 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001628280-26-008403. Last ingested by Listed: Oct 30, 2026, 08:51 ET. Listed shows no prices and gives no investment advice.